Comparison · NCT02012491-aba2b4fb
Misoprostol vs Misoprostol Plus Mifepristone: Uterine Asperation
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Misoprostol vs Misoprostol Plus Mifepristone: Uterine Asperation. Trial comparisons, record NCT02012491-aba2b4fb. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02012491-aba2b4fb
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.235 | 0.174 | 0.309 | wilson | |
| Risk in group 2 | 0.0878 | 0.0521 | 0.144 | wilson | |
| Risk difference, group 1 minus group 2 | 0.147 | 0.0639 | 0.229 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.67 | 1.48 | 4.85 | log | |
| Odds ratio, group 1 over group 2 | 3.19 | 1.61 | 6.32 | log | |
| Number needed to treat, for one more participant with the outcome on Misoprostol than on Misoprostol Plus Mifepristone | 6.8 | 4.36 | 15.6 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Misoprostol | 800 micrograms of vaginal misoprostol alone~Misoprostol | 35 | 149 | OG000 |
| Group 2 | Misoprostol Plus Mifepristone | 800 micrograms vaginal misoprostol, preceded by 200 milligrams oral mifepristone 24 hours prior~Misoprostol~Mifepristone | 13 | 148 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Uterine Asperation
- Description
- Surgical removal of the miscarriage.
- Time frame
- 30 Days
- Population
Source ClinicalTrials.gov
Trial
- Title
- Comparative Effectiveness of Pregnancy Failure Management Regimens
- NCT number
- NCT02012491
- Phases
- PHASE3
- Conditions
- Spontaneous Abortion
- Interventions
- Misoprostol, Mifepristone
- Lead sponsor
- University of Pennsylvania
- Results first posted
- 2018-12-21
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02012491?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02012491-aba2b4fb